A Feasibility Randomized Control Trial to Investigate the in Silico Optimization of Insulin Treatments

Status: Unknown status
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The primary objective of this study is to assess the performance of an in silico designed alternative protocol for control of stress hyperglycemia of inpatients treated for Coronary Artery Bypass Graft (CABG) or valve replacement surgery in the University of Virginia cardiothoracic ICU.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 75
Healthy Volunteers: No
View:

• Patients admitted for CABG and/or open heart valve surgery

• Must have a 0.05 initial multiplier setting for the Glucommander based on the manufacturers recommendations

• Age of 40-75, inclusive

Locations
United States
Virginia
University of Vrginia
Recruiting
Charlottesville
Contact Information
Primary
Anna Buhle
ab7ga@virginia.edu
4349898257
Backup
leon farhi, PhD
leon@virginia.edu
4342966583
Time Frame
Start Date: March 19, 2018
Completion Date: April 30, 2019
Participants
Target number of participants: 35
Treatments
Active Comparator: Standard Glucommander Protocol (SGP)
CABG or open valve surgery patients treated for stress hyperglycemia with the standard Glucomander protocol according to the manufacturer recommendations
Experimental: Optimized Glucommander (OGM)
CABG or open valve surgery patients treated for stress hyperglycemia with in silico optimized Glucomander protocol
Authors
Rachel Simon, J. Michael Cosner, Anna Buhle, Gorav Ailawadi, John Kern, Anthony L McCall, Leora Yarboro, Irving Kron, Jennifer Kirby, Stephen Patek, Leon S Farhi
Sponsors
Collaborators: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Leads: University of Virginia

This content was sourced from clinicaltrials.gov

Similar Clinical Trials